Related Experiment Videos
Impact of dexmedetomidine on hemodynamic changes during and after coronary artery bypass grafting
Morteza Hashemian1, Mehdi Ahmadinejad1, Seyed Amir Mohajerani2
1Department of Anesthesiology and Pain Medicine, Kerman University of Medical Sciences, Kerman, Iran.
Insights
Dexmedetomidine (Dex) effectively managed hemodynamic changes during coronary artery bypass grafting (CABG) surgery. This anesthetic agent helped maintain stable blood pressure and lower heart rate, reducing surgical stress in patients.
Area of Science:
- Anesthesiology and Critical Care Medicine
- Cardiovascular Surgery
- Pharmacology
Background:
- Coronary artery bypass grafting (CABG) involves significant hemodynamic stress.
- Managing intraoperative and postoperative hemodynamics is crucial for patient outcomes.
- Dexmedetomidine (Dex) is an alpha-2 adrenergic agonist with sedative and analgesic properties.
Purpose of the Study:
- To evaluate the impact of dexmedetomidine (Dex) infusion on hemodynamic parameters during and after CABG surgery.
- To compare the effects of Dex versus placebo on heart rate (HR), blood pressure (BP), and pain management.
Main Methods:
- A double-blinded, randomized clinical trial was conducted at a university hospital.
- Patients undergoing elective CABG received either Dex (0.5 μg/kg/h) or a placebo from anesthesia induction to extubation.
- Hemodynamic variables (HR, BP), pain scores, and morphine requirements were monitored during cardiopulmonary bypass and for 12 hours postoperatively.
Main Results:
- The Dex group exhibited significantly higher mean arterial pressure at 1 and 2 hours postoperatively compared to the control group.
- Heart rate was significantly lower in the Dex group during cardiopulmonary bypass and in the early postoperative period.
- Postoperative pain scores were significantly reduced in patients receiving Dex for up to 12 hours.
Conclusions:
- Dexmedetomidine effectively blunts hemodynamic responses to surgical stress in CABG patients.
- Continuous Dex infusion helps maintain blood pressure within a higher range and heart rate at a lower range compared to placebo.
- Dex may improve hemodynamic stability and pain control following cardiac surgery.
Objective:
To determine the effect of dexmedetomidine (Dex) on hemodynamic changes during cardiopulmonary pump and postoperative period in coronary artery bypass grafting (CABG).
Methods And Design:
This study is designed as a double-blinded, randomized clinical trial.
Setting:
University hospital and single center.
Participants:
patients candidate for elective CABG.
Intervention:
Dex 0.5 μg/kg/h or placebo was infused from the initiation of anesthesia up to extubation in Intensive Care Unit (ICU).
Measurements:
Heart rate (HR) and blood pressure (BP), pain score, and total morphine dose requirement were monitored and compared during cardiac pump up to 12 h postoperative in ICU.
Results:
Mean arterial pressure was significantly higher in Dex group in postoperation period at 1 (P = 0.010) and 2 h (P = 0.002) compared to control group. HR was significantly lower in Dex group in postcardiopulmonary bypass (CPB) time at 0 h (P = 0.001), 1 h (P = 0.0016), and 2 h (P = 0.001), and then in postoperative period in ICU at 1 h (P = 0.025), 2 h (P = 0.0012), and 4 h (P = 0.0025) compared to control group. Postoperative pain score was significantly lower during 12 h after surgery.
Conclusion:
Dex could effectively blunt hemodynamic response to surgical stress, particularly during CPB pump and afterward. Infusion of Dex maintains BP at higher range and HR at lower range compared to placebo.